Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this currently Zacks ...

According to TipRanks.com, Lee is a top 100 analyst with an average return of 35.1% and a 57.3% success rate. Lee covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, ...

Glaukos (GKOS) shares rallied 3.7% in the last trading session to close at $116.66. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The ...

Is Glaukos Corporation (NYSE:GKOS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Glaukos Corporation has experienced two significant technical analysis developments over the past 20 weeks. GKOS stock price gains are being driven by strong top-line growth, but profitability trends ...

Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. Revising to buy on fundamental, sentimental ...

Forbes contributors publish independent expert analyses and insights. Now, after a a large 34% fall in a week, will GKOS stock continue its downward trajectory over the coming weeks, or is a recovery ...

Glaukos Corporation GKOS is well-poised for growth on the back of the iDose TR launch and a robust product pipeline. However, ...